Endostatin a Potential Biomarker for Heart Failure with Preserved Ejection Fraction

Endostatin a Potential Biomarker for Heart Failure with Preserved Ejection Fraction

BACKGROUND Endostatin is a circulating endogenous angiogenesis inhibitor preventing neovascularization. Previous studies demonstrated the prognostic value of Endostatin among patients with heart failure with reduced ejection fraction (HFrEF). However, the role of Endostatin among patients with heart failure with preserved ejection fraction (HFpEF) remains unclear. OBJECTIVE This study aimed t...

Heart Failure With Preserved Ejection Fraction

The Journal of the American Osteopathic Association July 2015 | Vol 115 | No. 7 432 From Henry Ford Wyandotte Downriver Cardiology in Brownstown, Michigan (Dr Rogers); West Suburban Medical Center in Oak Park, Illinois (Dr Gundala); Oakwood Southshore Medical Center in Trenton, Michigan (Dr Ramos); and Elmhurst Memorial Hospital in Illinois (Dr Serajian). Drs Gundala and Ramos are in their thir...

Heart Failure With Preserved Ejection Fraction

Symptomatic heart failure, despite preserved left ventricular (LV) ejection fraction, is a well-recognized phenomenon. This manifestation of diastolic dysfunction is associated with increased morbidity and mortality and can be attributed to a variety of pathogeneses, including diabetes mellitus, hypertension, infiltrative processes, and obesity. Unlike in systolic heart failure, where LV ejecti...

[Heart failure with preserved ejection fraction (HFpEF)].

Heart Failure with Preserved Ejection Fraction

1. Demonstrate the association between heart failure with preserved ejection fraction (HFpEF) and survival. 2. Given a patient with heart failure (HF), recognize HFpEF on the basis of clinical signs and symptoms, physical examination, echocardiography, and radiographic findings. 3. Classify patients at high risk of hospitalization and mortality through assessing risk factors, clinical presentat...